Analyst Sentiment on Outset Medical (OM) Remains Strong Following Q4 Results

Core Viewpoint - Outset Medical, Inc. (NASDAQ:OM) has shown resilience in its stock performance despite a decline in price targets from analysts following its fourth-quarter results, which largely met expectations [2][8]. Financial Performance - The fourth-quarter revenue for Outset Medical was reported at $28.90 million, reflecting a 2% year-over-year decrease [4]. - Total revenue for the year 2025 was $119.50 million, marking a 5% increase compared to the previous year [4]. - The full-year margin improved to 39.10%, while the quarterly gross margin increased by 600 basis points to 42.40% [4]. Analyst Insights - Analysts from TD Cowen and BTIG have adjusted their price targets to $12 and $15 respectively, while maintaining 'Buy' ratings, indicating continued confidence in the stock [2]. - BTIG highlighted that a stable sales force, an upcoming product launch, a wide deal pipeline, robust recurring revenue, and improving margins are expected to help restore the company's credibility [3]. Future Projections - Management has projected 2026 revenue to be between $125 million and $130 million, with a non-GAAP gross margin anticipated in the low-to-mid-40% range [5]. - The company plans to launch its next-generation Tablo platform in the second quarter of 2026 [5]. Company Overview - Outset Medical, founded in 2003 in San Jose, specializes in dialysis solutions through its Tablo Hemodialysis System, which facilitates both acute and home treatment [6].